Spark Therapeutics (ONCE) Upgraded at B. Riley

Share on StockTwits

B. Riley upgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a neutral rating to a buy rating in a report published on Wednesday morning, MarketBeat.com reports. B. Riley currently has $71.00 price target on the biotechnology company’s stock, up from their prior price target of $68.00. B. Riley also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($1.34) EPS, FY2018 earnings at ($1.70) EPS, Q1 2019 earnings at ($1.06) EPS, Q2 2019 earnings at ($1.02) EPS, Q3 2019 earnings at ($0.83) EPS, Q4 2019 earnings at $0.69 EPS, FY2019 earnings at ($3.87) EPS, FY2020 earnings at $1.78 EPS, FY2021 earnings at $3.56 EPS and FY2022 earnings at $3.59 EPS.

A number of other research analysts have also issued reports on ONCE. Cantor Fitzgerald set a $103.00 target price on Spark Therapeutics and gave the stock a buy rating in a report on Monday, July 16th. Royal Bank of Canada lowered Spark Therapeutics from an outperform rating to a sector perform rating and set a $100.00 target price on the stock. in a report on Thursday, July 19th. ValuEngine lowered Spark Therapeutics from a strong-buy rating to a buy rating in a report on Tuesday, July 24th. Citigroup raised Spark Therapeutics from a neutral rating to a buy rating in a report on Tuesday, August 7th. Finally, Leerink Swann reaffirmed a market perform rating and set a $55.00 target price (down from $74.00) on shares of Spark Therapeutics in a report on Tuesday, August 7th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $68.52.

Shares of ONCE traded down $3.24 during trading hours on Wednesday, reaching $42.76. 666,734 shares of the company’s stock traded hands, compared to its average volume of 567,755. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -5.60 and a beta of 2.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.14 and a current ratio of 10.71. Spark Therapeutics has a twelve month low of $39.01 and a twelve month high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $27.44 million. Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. Spark Therapeutics’s revenue was up 463.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.90) earnings per share. Analysts forecast that Spark Therapeutics will post -1.44 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Aperio Group LLC increased its stake in Spark Therapeutics by 23.5% in the 2nd quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock worth $459,000 after purchasing an additional 1,056 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in Spark Therapeutics by 2.7% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock worth $3,412,000 after purchasing an additional 1,075 shares in the last quarter. Amalgamated Bank increased its stake in Spark Therapeutics by 29.7% in the 2nd quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 1,100 shares in the last quarter. Smith Asset Management Group LP increased its stake in Spark Therapeutics by 39.6% in the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 1,120 shares in the last quarter. Finally, Capital Fund Management S.A. increased its stake in Spark Therapeutics by 8.1% in the 2nd quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock worth $1,273,000 after purchasing an additional 1,152 shares in the last quarter.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Recommended Story: Understanding Market Liquidity

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.